The deal structure involves an upfront cash payment of $90 million at closing, with two deferred payments of $25 million each scheduled for the first and second anniversaries of the closing date. This acquisition is expected to contribute between $2 million to $4 million in revenue for the remainder of 2026, although it will dilute Merit’s previously forecasted non-GAAP earnings per share by approximately $0.05. Despite this initial dilution, the acquisition is projected to be accretive to non-GAAP earnings per share in 2027, with anticipated revenue growth of at least 20% per year from the OneMark System, which boasts a gross margin of 70%.
Martha G. Aronson, President and CEO of Merit, emphasized the strategic importance of this acquisition, stating, "This acquisition expands Merit’s portfolio of therapeutic oncology products dedicated to the accurate diagnosis and localization of breast and soft tissue tumors." The integration of View Point’s ultrasound-enhanced technology with Merit’s existing SCOUT® platform is expected to provide physicians with enhanced localization options, potentially reducing the need for additional procedures prior to surgery.
Merit plans to discuss the acquisition in further detail during its first-quarter investor conference call scheduled for April 30, 2026. The company’s leadership is optimistic about the long-term benefits of this acquisition, which aligns with its mission to reduce the burden of breast cancer on patients and their families. As the market for innovative oncology solutions continues to grow, this acquisition positions Merit Medical Systems as a key player in the therapeutic oncology landscape.
